AMPH

AI MemoPost-earnings T+3

Amphastar

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results modestly exceeded pre-release expectations • 2026-08-06

Base target: $22 / p=55% prob

Biggest risk

Adjusted EPS declined year over year in Q2 and first-half adjusted EPS fell to $1.33 from $1.59. BAQSIMI faced lower pricing, glucagon revenue fell 42%, and competition affected epinephrine and glucagon. No post-print analyst target, rating, or estimate revisions were available in the evidence packet.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The Q2 print showed 5% revenue growth, 8% gross-profit growth, 50.8% gross margin, successful Ipratropium launch, and continued growth from newer products. The approximately 4.8% move versus the prior close suggests the market initially viewed the print favorably.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$22

p=55%

Bull target

$27

p=20%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion of commercial mix
Commercial uptake from recently launched products
Pipeline and licensing optionality remains longer dated

BearKey bullets

Competition pressured epinephrine and glucagon, while the BAQSIMI milestone triggers a $100 million payment to Lilly in Q3 2026 [#SEC-8K-2026-08-06].
Forward visibility remains limited because post-earnings analyst revisions and detailed transcript digestion were unavailable.
Glucagon revenue declined 42% year over year because of lower pricing, lower volume, and continued customer shift toward ready-to-use products [#SEC-8K-2026-08-06].

WatchKey bullets

Q2 2026 results modestly exceeded pre-release expectations

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $22 (p=55%)

Target spread vs base: +23% / -20%

Scenario probabilities

Bull Target: $27 (p=20%)Base Target: $22 (p=55%)Bear Target: $18 (p=25%)

Commentary

The T3 follow-up confirms a modest Q2 beat and an initially positive price response, but the earnings mix was uneven and no post-print analyst revisions were available. Social coverage was absent, and low analyst coverage plus loose peers reduce confidence in a stronger directional thesis. Sentiment is cautiously positive but best treated as monitoring-oriented.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion of commercial mix
Commercial uptake from recently launched products
Pipeline and licensing optionality remains longer dated

Scenarios

Bull Target (Scenario probability)

$27 / p=20% prob

Base Target (Scenario probability)

$22 / p=55% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.05

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 results modestly exceeded pre-release expectations
Amphastar reported Q2 revenue of $183.9 million and GAAP EPS of $0.67, versus stored pre-release Zacks estimates of $181.94 million and $0.66; adjusted EPS was $0.91. Management cited revenue growth, gross-margin expansion, new-product launches, and pipeline progress, while also flagging pricing and competitive pressure [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-30].
Prob 70.00% • Move 5.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion of commercial mix
2026-08-15
Near-term sentiment depends on whether the modest earnings beat and 50.8% gross margin offset weakness in BAQSIMI pricing, glucagon, and epinephrine. The latest market feed showed AMPH at $20.78, up approximately 4.8% versus the prior close, but attribution of the move to earnings is unconfirmed.
Prob 55% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

Commercial uptake from recently launched products
2026-12-31
Ipratropium bromide generated $8.4 million after its April 2026 launch, while iron sucrose and teriparatide contributed year-over-year growth and albuterol volumes continued to improve. Sustained uptake could help offset legacy-product erosion, but competition and pricing remain material constraints [#SEC-8K-2026-08-06].
Prob 55% • Move 11% • Priced-in 45%
Pipeline and licensing optionality remains longer dated
2027-06-30
The company’s proprietary pipeline and the 2026 corticotropin licensing transaction provide optionality beyond the current commercial portfolio, but development, regulatory, milestone, and commercialization visibility remains limited [#8-K-2026-01-06].
Prob 35% • Move 15% • Priced-in 20%

Risks

Competition pressured epinephrine and glucagon, while the BAQSIMI milestone triggers a $100 million payment to Lilly in Q3 2026 [#SEC-8K-2026-08-06].
Forward visibility remains limited because post-earnings analyst revisions and detailed transcript digestion were unavailable.
Glucagon revenue declined 42% year over year because of lower pricing, lower volume, and continued customer shift toward ready-to-use products [#SEC-8K-2026-08-06].
Pricing and customer-mix changes reduced BAQSIMI revenue despite higher unit volume [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
COLL	Commercial specialty-pharma exposure provides some operating context, but product mix and scale differ materially from Amphastar.
GERN	Small-cap biopharma with commercialization and pipeline-transition risk; useful for sentiment context but not a direct operating comparable.
ABUS	Small-cap biopharma size peer with different pipeline economics; supports only broad valuation and risk framing.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

COLL

Commercial specialty-pharma exposure provides some operating context, but product mix and scale differ materially from Amphastar.

GERN

Small-cap biopharma with commercialization and pipeline-transition risk; useful for sentiment context but not a direct operating comparable.

ABUS

Small-cap biopharma size peer with different pipeline economics; supports only broad valuation and risk framing.